Coronavirus: Commission concludes exploratory talks with Valneva to secure a new potential vaccine
Today, the European Commission concluded exploratory talks with the pharmaceutical company Valneva with a view to purchasing its potential vaccine against COVID-19. The envisaged contract with Valneva would provide for the possibility for all EU Member States to purchase together 30 million doses, and they could further purchase up to 30 million more doses.
Today's finalisation of exploratory talks with Valneva come in addition to an already secured broad portfolio of vaccines to be produced in Europe, including the contracts already signed with AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica NV, BioNtech-Pfizer, CureVac, and Moderna and exploratory talks concluded with Novavax. This diversified vaccines portfolio will ensure Europe is well prepared for vaccination, once the vaccines have been proven to be safe and effective, as is already the case for BioNTech/Pfizer and Moderna, recently authorised in the EU. Member States are able to donate vaccines to lower and middle-income countries or to re-direct it to other European countries.
President of the European Commission, Ursula von der Leyen, said:
"The continuing COVID-19 pandemic in Europe and around the globe makes it more important than ever that all Member States have access to the broadest possible portfolio of vaccines to help protect people in Europe and beyond. Today's step toward reaching an agreement with Valneva further complements the EU's vaccines portfolio and demonstrates the Commission's commitment to find a lasting solution to the pandemic."
Stella Kyriakides, Commissioner for Health and Food Safety, said:
"With this eighth vaccine, we are adding to our already broad and diversified range of vaccines in our portfolio. By doing this, we can maximise our chances of making sure that all citizens can have access to safe and effective of vaccinations by the end of 2021. All Member States have now started their vaccination campaigns and will start receiving an increasing number of doses in order to cover all their needs during this year."
Valneva is a European biotechnology company developing an inactivated virus vaccine. This is a traditional vaccine technology, used for 60-70 years, with established methods and a high level of safety. Most of the influenza vaccines and many childhood vaccines use this technology. This is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe.
The Commission, with the support of EU Member States, has taken a decision to support this vaccine based on a sound scientific assessment, the technology used, the company's experience in vaccine development and its production capacity to supply all EU Member States.
Latest News from
Panel of experts confirms Korea is in breach of labour commitments under our trade agreement25/01/2021 13:25:00
The panel report published today confirms the EU's concerns that Korea has not acted consistently with its trade and sustainable development obligations under the EU-Korea trade agreement.
"Challenge, resilience and accountability: the path to transformation" - Speech by President Charles Michel at the EIB Annual Economic Conference25/01/2021 11:33:00
Speech given recently (22 January 2021) by President Charles Michel at the EIB Annual Economic Conference.
Readout of the telephone conversation between President Charles Michel and Russian President Vladimir Putin25/01/2021 10:38:00
The phone call between the President of the European Council Charles Michel and President Vladimir Putin of the Russian Federation took place on Friday 22 January 2021.
‘Right to disconnect’ should be an EU-wide fundamental right, MEPs say25/01/2021 09:25:00
Parliament calls for an EU law that grants workers the right to digitally disconnect from work without facing negative repercussions.
Human rights breaches in Hong Kong, Turkey and Vietnam22/01/2021 16:33:00
On Thursday, Parliament adopted three resolutions taking stock of the human rights situation in Hong Kong, Turkey and Vietnam.
EU tax haven blacklist is not catching the worst offenders22/01/2021 15:25:00
MEPs adopted a resolution pushing for the system used to draw up the EU list of tax havens to be changed, as it is currently “confusing and ineffective”.
Council agrees on strengthening the use of rapid antigen tests and on the mutual recognition of COVID-19 test results22/01/2021 14:33:00
Member states yesterday unanimously agreed, by written procedure, on a Council recommendation setting a common framework for the use of rapid antigen tests and the mutual recognition of COVID-19 test results across the EU.
Commission welcomes agreement on additional financial support for the most deprived under REACT-EU22/01/2021 13:25:00
The European Parliament has voted through the political agreement reached by the co-legislators on the Commission's proposal to provide more funds to support the most deprived in Europe in the recovery phase.
Parliament demands significantly tighter EU sanctions against Russia22/01/2021 12:38:00
Following the recent imprisonment of Alexei Navalny, MEPs call on EU countries to significantly strengthen sanctions against Russia.